10-Q: Assure Holdings Corp. Reports Q1 2024 Results Amid Strategic Shift and Merger Plans

Assure Holdings Corp. announces its Q1 2024 financial results, highlighting a strategic shift involving the sale of clinical operations and a pending merger with Danam Health, Inc.

Summary

• Assure Holdings Corp. reported a net loss of $3.761 million for the quarter ended March 31, 2024, compared to a net loss of $3.144 million for the same period in 2023.
• Revenue decreased significantly to $9 thousand from $115 thousand year-over-year, primarily due to the company exiting managed service agreements.
• The company sold most of its clinical operations to MPOWER Health for up to $4.5 million, receiving $2.3 million in cash at closing and potentially up to $2.2 million in earnout payments.
• Assure entered into a merger agreement with Danam Health, Inc., expected to close in the future, with former Assure equity holders owning approximately 10% of the combined company.
• The company is addressing Nasdaq listing deficiencies and has been granted an extension until July 22, 2024, to regain compliance.
• Assure's current cash balance and estimated cash from operations are insufficient to meet its working capital needs for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
• The company settled a DOJ investigation for approximately $1 million, payable in monthly installments.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with declining revenue, net losses, and doubts about the company's ability to continue as a going concern. While there are some positive developments, such as the asset sale and merger agreement, the overall outlook is negative.

Positives

• The sale of clinical assets to MPOWER Health generated $2.3 million in cash at closing.
• The merger agreement with Danam Health, Inc. could provide a path forward for the company.
• The company received an extension from Nasdaq to regain compliance with listing requirements.
• The settlement with the DOJ resolves a legal uncertainty.
• The company settled certain amounts of accounts payable for less than the original amounts owed which resulted in a gain of $181 thousand.

Negatives

• Revenue decreased significantly to $9 thousand.
• The company reported a net loss of $3.761 million.
• There is substantial doubt about Assure's ability to continue as a going concern.
• The company is not in compliance with debt covenants.
• The company has material weaknesses in internal controls over financial reporting.

Risks

• The company's ability to continue as a going concern is uncertain.
• Failure to regain compliance with Nasdaq listing requirements could result in delisting.
• The merger with Danam Health, Inc. may not be completed.
• The company may not be able to secure additional financing on acceptable terms.
• The company is exposed to credit risk from accounts receivable.
• The company is dependent on Centurion granting certain add-backs and other one-time adjustments in the calculation of financial covenants related to EBITDA related to the Centurion debt.

Future Outlook

The company is focused on completing the merger with Danam Health, Inc. and regaining compliance with Nasdaq listing requirements. Assure intends to seek equity or debt financing and have implemented significant cost cutting measures to mitigate its going concern.

Industry Context

The IONM industry is competitive, with companies like NuVasive and Medtronic also offering neuromonitoring services. Assure's strategic shift reflects a move to adapt to changing market conditions and focus on profitability.

Comparison to Industry Standards

• It is difficult to compare Assure's results directly to industry standards due to its strategic shift and pending merger.
• Companies like NuVasive and Medtronic, which offer IONM services, have significantly larger revenue bases and broader product portfolios.
• Smaller IONM providers may face similar challenges in terms of reimbursement and regulatory compliance.

Legal Proceedings

• The company settled a DOJ investigation for approximately $1 million, payable in monthly installments.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by cost-cutting measures.
• Customers may experience changes in service delivery due to the sale of clinical operations.
• Creditors face increased risk due to the company's financial difficulties.

Next Steps

• Complete the merger with Danam Health, Inc.
• Regain compliance with Nasdaq listing requirements.
• Seek equity or debt financing.
• Implement cost-cutting measures.

Key Dates

Keywords

merger, neuromonitoring, IONM, financial results, Danam Health, Assure Holdings, going concern, Nasdaq, clinical operations, MPOWER Health